AR070408A1 - Piridinonas y piridazinonas - Google Patents
Piridinonas y piridazinonasInfo
- Publication number
- AR070408A1 AR070408A1 ARP090100345A ARP090100345A AR070408A1 AR 070408 A1 AR070408 A1 AR 070408A1 AR P090100345 A ARP090100345 A AR P090100345A AR P090100345 A ARP090100345 A AR P090100345A AR 070408 A1 AR070408 A1 AR 070408A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- lower alkyl
- hydroxy
- halogen
- amino
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 18
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- -1 nitro, amino Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000003368 amide group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000002923 oximes Chemical class 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos aquí descritos son utiles para modular la actividad de la Btk y tratar enfermedades asociadas con una actividad excesiva de la Btk. Además, estos compuestos son utiles para tratar enfermedades inflamatorias y autoinmunes asociadas con la proliferacion aberrante de células B, por ejemplo la artritis reumatoide. Se describen también composiciones que contienen los compuestos de las formulas (1) - (3) y por lo menos un vehículo, diluyente o excipiente. Reivindicacion 1: Un compuesto de las formulas (1), (2) o (3) en las que: R es H, -R1, -R1-R2-R3, -R1-R3 o -R2-R3; R1 es arilo, heteroarilo, cicloalquilo o heterocicloalquilo y está opcionalmente sustituido por uno o más alquilo inferior, hidroxi, hidroxi-alquilo inferior, alcoxi inferior, halogeno, nitro, amino, amido, ciano, oxo o halo-alquilo inferior; R2 es -C(=O), -C(=O)O, -C(=O)NR2', -NHC(=O)O, -C(=NH)NR2' o -S(=O)2; en los que R2' es H o alquilo inferior; R3 es H o R4; en el que R4 es alquilo inferior, amino, arilo, arilalquilo, alquilarilo, heteroarilo, alquil-heteroarilo, heteroaril-alquilo, cicloalquilo, alquil-cicloalquilo, cicloalquil-alquilo, heterocicloalquilo, alquil-heterocicloalquilo o heterocicloalquil-alquilo y está opcionalmente sustituido por uno o más alquilo inferior, hidroxi, alcoxi inferior, hidroxi-alquilo inferior, hidroxi-alcoxi inferior, (alquilo inferior)-sulfonilo, (alquilo inferior)-sulfonamido, carbamato, carboxi, éster, amido, acilo, halogeno, nitro, amino, ciano, oxo o haloalquilo inferior; X es CH o N; Y1 es H, alquilo inferior o haloalquilo inferior; cada Y2 es con independencia halogeno, oxima o alquilo inferior, dicho alquilo inferior está opcionalmente sustituido por uno o más sustituyentes elegidos entre el grupo formado por hidroxi, alcoxi inferior, haloalcoxi inferior, haloalquilo inferior, carboxi, amino y halogeno; n es el numero 0, 1, 2 o 3; Y3 es H, halogeno o alquilo inferior, dicho alquilo inferior está opcionalmente sustituido por uno o más sustituyentes elegidos entre el grupo formado por hidroxi, alcoxi inferior, amino y halogeno; m es el numero 0 o 1; Y4 es Y4a, Y4b, Y4c o Y4d; en el que Y4a es H o halogeno; Y4b es alquilo inferior, opcionalmente sustituido por uno o más sustituyentes elegidos entre el grupo formado por haloalquilo inferior, halogeno, hidroxi, amino, ciano y alcoxi inferior; Y4c es cicloalquilo inferior, opcionalmente sustituido con uno o más sustituyentes elegidos entre el grupo formado por alquilo inferior, haloalquilo inferior, halogeno, hidroxi, amino, ciano y alcoxi inferior; e Y4d es amino, opcionalmente sustituido por uno o más alquilo inferior, alcoxi-alquilo inferior o hidroxi-alquilo inferior; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2620408P | 2008-02-05 | 2008-02-05 | |
| US12251008P | 2008-12-15 | 2008-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070408A1 true AR070408A1 (es) | 2010-04-07 |
Family
ID=40413736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100345A AR070408A1 (es) | 2008-02-05 | 2009-02-03 | Piridinonas y piridazinonas |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP2242749B1 (es) |
| JP (1) | JP5259739B2 (es) |
| KR (1) | KR101308803B1 (es) |
| CN (1) | CN101932573B (es) |
| AR (1) | AR070408A1 (es) |
| AU (1) | AU2009211514B2 (es) |
| BR (1) | BRPI0907915A2 (es) |
| CA (1) | CA2710462C (es) |
| CL (1) | CL2009000229A1 (es) |
| CO (1) | CO6290767A2 (es) |
| CR (1) | CR11598A (es) |
| CY (1) | CY1114114T1 (es) |
| DK (1) | DK2242749T3 (es) |
| EC (1) | ECSP10010384A (es) |
| ES (1) | ES2420846T3 (es) |
| HR (1) | HRP20130615T1 (es) |
| IL (1) | IL206357A (es) |
| MA (1) | MA32064B1 (es) |
| MX (1) | MX2010008197A (es) |
| MY (1) | MY158411A (es) |
| NZ (1) | NZ586916A (es) |
| PE (1) | PE20091484A1 (es) |
| PL (1) | PL2242749T3 (es) |
| PT (1) | PT2242749E (es) |
| RU (1) | RU2505538C2 (es) |
| SI (1) | SI2242749T1 (es) |
| TW (1) | TWI382024B (es) |
| WO (1) | WO2009098144A1 (es) |
| ZA (1) | ZA201005539B (es) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2728016C (en) | 2008-06-24 | 2017-02-28 | F. Hoffmann-La Roche Ag | Novel substituted pyridin-2-ones and pyridazin-3-ones |
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| SG175287A1 (en) * | 2009-04-24 | 2011-11-28 | Hoffmann La Roche | Inhibitors of bruton's tyrosine kinase |
| PL2473049T3 (pl) | 2009-09-04 | 2019-07-31 | Biogen Ma Inc. | Inhibitory kinazy tyrozynowej brutona |
| CN110818724B (zh) * | 2010-05-07 | 2020-11-13 | 吉利德康涅狄格有限公司 | 吡啶酮和氮杂吡啶酮化合物及使用方法 |
| EP2394998A1 (en) * | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| ES2590491T3 (es) * | 2011-05-17 | 2016-11-22 | F. Hoffmann-La Roche Ag | Inhibidores de la tirosina quinasa de Bruton |
| CA2841801A1 (en) * | 2011-08-17 | 2013-02-21 | F.Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US9365566B2 (en) | 2012-03-27 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives |
| BR112014024693A2 (pt) | 2012-04-05 | 2017-07-11 | Chdi Foundation Inc | composto de fórmula / ou um sal farmaceuticamente aceitável ou pró-fármaco do mesmo; composto; composição farmacêutica; método de tratamento de uma afecção ou distúrbio mediado por atividade de quinurenina 3-mono-oxigenase em um indivíduo que necessita de tal tratamento |
| CN104662018B (zh) | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | 取代的杂双环化合物、组合物及其医疗应用 |
| AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| KR20150054994A (ko) * | 2012-09-13 | 2015-05-20 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
| WO2014076104A1 (en) * | 2012-11-16 | 2014-05-22 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| RU2015122218A (ru) * | 2012-11-30 | 2017-01-10 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы тирозинкиназы брутона |
| JP6089124B2 (ja) | 2013-03-05 | 2017-03-01 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルトン型チロシンキナーゼの阻害薬 |
| EP2964642B1 (en) * | 2013-03-05 | 2017-11-15 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
| JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| ES2619125T3 (es) | 2013-04-25 | 2017-06-23 | Beigene, Ltd. | Compuestos heterocíclicos fusionados como inhibidores de proteína cinasa |
| CN104177338B (zh) * | 2013-05-22 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类布鲁顿激酶抑制剂 |
| CA2912359A1 (en) * | 2013-07-03 | 2015-01-08 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone amide compounds |
| IL296026B2 (en) | 2013-09-13 | 2024-10-01 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| KR101813830B1 (ko) * | 2013-12-05 | 2017-12-29 | 에프. 호프만-라 로슈 아게 | 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물 |
| JP6526189B2 (ja) | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用 |
| JP6507234B2 (ja) * | 2014-10-02 | 2019-04-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルトンチロシンキナーゼ（ｂｔｋ）によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物 |
| JP6916185B2 (ja) * | 2016-01-13 | 2021-08-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋ阻害剤としてのイソキノロン類 |
| PL3436447T3 (pl) | 2016-03-31 | 2021-12-27 | Takeda Pharmaceutical Company Limited | Kompleksy triazolonu izochinolinylowego |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| WO2018017153A1 (en) | 2016-07-21 | 2018-01-25 | Biogen Ma Inc. | Succinate forms and compositions of bruton's tyrosine kinase inhibitors |
| SG11201901141WA (en) | 2016-08-16 | 2019-03-28 | Beigene Ltd | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| PT3500299T (pt) | 2016-08-19 | 2024-02-21 | Beigene Switzerland Gmbh | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro |
| EP3515414B1 (en) | 2016-09-19 | 2022-11-30 | MEI Pharma, Inc. | Combination therapy |
| CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
| CN106967073A (zh) * | 2017-04-24 | 2017-07-21 | 刘双伟 | 一种治疗类风湿性关节炎的药物 |
| CN108164536A (zh) * | 2017-05-08 | 2018-06-15 | 刘双伟 | 一种用于治疗类风湿性关节炎的新的化合物的合成方法 |
| TWI877099B (zh) | 2017-06-26 | 2025-03-21 | 英屬開曼群島商百濟神州有限公司 | 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途 |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| BR112021007115A2 (pt) | 2018-10-15 | 2021-07-20 | Nurix Therapeutics, Inc. | compostos bifuncionais para dedradação de btk por meio da via de proteossoma de ubiquitina |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| CN114364667B (zh) | 2019-04-09 | 2025-01-10 | 紐力克斯治疗公司 | 用于Cbl-b抑制的3-取代哌啶类化合物以及Cbl-b抑制剂与癌症疫苗和/或溶瘤病毒联合的用途 |
| CA3140873A1 (en) | 2019-05-17 | 2020-11-26 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| TWI856111B (zh) | 2019-06-10 | 2024-09-21 | 瑞士商百濟神州瑞士有限責任公司 | 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法 |
| US11401267B2 (en) | 2019-06-26 | 2022-08-02 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| US20230024442A1 (en) * | 2019-11-08 | 2023-01-26 | Nurix Therapeutics, Inc. | Bifunctional compounds for grading btk via ubiquitin proteosome pathway |
| WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| JP2024514836A (ja) | 2021-04-08 | 2024-04-03 | ニューリックス セラピューティクス，インコーポレイテッド | Ｃｂｌ－ｂ阻害化合物との組み合わせ療法 |
| EP4422630A1 (en) | 2021-10-26 | 2024-09-04 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3951395B2 (ja) * | 1996-12-13 | 2007-08-01 | 田辺製薬株式会社 | ピリジン誘導体、その製法及びその合成中間体 |
| RU2242474C2 (ru) * | 1999-03-12 | 2004-12-20 | Бёрингер Ингельхайм Фармасьютиклз, Инк. | Соединения, пригодные в качестве противовоспалительных агентов |
| ES2232306B1 (es) * | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| KR20070095952A (ko) * | 2004-12-16 | 2007-10-01 | 버텍스 파마슈티칼스 인코포레이티드 | 염증성 질환, 증식성 질환 및 면역학적으로 매개된 질환치료용 Ｔｅｃ 계열 단백질 키나제의 억제제로서 유용한피리드-2-온 |
| MY140868A (en) * | 2004-12-24 | 2010-01-29 | Astrazeneca Ab | Amide derivatives |
| AU2006223409B2 (en) * | 2005-03-10 | 2011-07-21 | Gilead Connecticut, Inc. | Certain substituted amides, method of making, and method of use thereof |
| WO2006124731A2 (en) * | 2005-05-12 | 2006-11-23 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| BRPI0614804A2 (pt) * | 2005-08-09 | 2011-04-12 | Irm Llc | compostos e composições como inibidores de proteìna cinase |
| CA2620269A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
| KR20080109095A (ko) * | 2006-05-15 | 2008-12-16 | 아이알엠 엘엘씨 | Ｆｇｆ 수용체 키나제 억제제를 위한 조성물 및 방법 |
-
2009
- 2009-01-27 JP JP2010545433A patent/JP5259739B2/ja not_active Expired - Fee Related
- 2009-01-27 EP EP09709135.9A patent/EP2242749B1/en not_active Not-in-force
- 2009-01-27 BR BRPI0907915-7A patent/BRPI0907915A2/pt not_active IP Right Cessation
- 2009-01-27 CA CA2710462A patent/CA2710462C/en not_active Expired - Fee Related
- 2009-01-27 HR HRP20130615AT patent/HRP20130615T1/hr unknown
- 2009-01-27 SI SI200930630T patent/SI2242749T1/sl unknown
- 2009-01-27 KR KR1020107016014A patent/KR101308803B1/ko not_active Expired - Fee Related
- 2009-01-27 DK DK09709135.9T patent/DK2242749T3/da active
- 2009-01-27 MX MX2010008197A patent/MX2010008197A/es active IP Right Grant
- 2009-01-27 MY MYPI2010003693A patent/MY158411A/en unknown
- 2009-01-27 PL PL09709135T patent/PL2242749T3/pl unknown
- 2009-01-27 CN CN200980103857.3A patent/CN101932573B/zh not_active Expired - Fee Related
- 2009-01-27 WO PCT/EP2009/050875 patent/WO2009098144A1/en not_active Ceased
- 2009-01-27 ES ES09709135T patent/ES2420846T3/es active Active
- 2009-01-27 AU AU2009211514A patent/AU2009211514B2/en not_active Expired - Fee Related
- 2009-01-27 PT PT97091359T patent/PT2242749E/pt unknown
- 2009-01-27 RU RU2010136665/04A patent/RU2505538C2/ru not_active IP Right Cessation
- 2009-01-27 NZ NZ586916A patent/NZ586916A/en not_active IP Right Cessation
- 2009-02-03 AR ARP090100345A patent/AR070408A1/es not_active Application Discontinuation
- 2009-02-03 TW TW098103399A patent/TWI382024B/zh not_active IP Right Cessation
- 2009-02-03 CL CL2009000229A patent/CL2009000229A1/es unknown
- 2009-02-04 PE PE2009000169A patent/PE20091484A1/es not_active Application Discontinuation
-
2010
- 2010-06-14 IL IL206357A patent/IL206357A/en not_active IP Right Cessation
- 2010-07-26 CO CO10090865A patent/CO6290767A2/es active IP Right Grant
- 2010-07-27 CR CR11598A patent/CR11598A/es not_active Application Discontinuation
- 2010-08-03 ZA ZA2010/05539A patent/ZA201005539B/en unknown
- 2010-08-05 EC EC2010010384A patent/ECSP10010384A/es unknown
- 2010-08-06 MA MA33066A patent/MA32064B1/fr unknown
-
2013
- 2013-07-08 CY CY20131100576T patent/CY1114114T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070408A1 (es) | Piridinonas y piridazinonas | |
| AR072545A1 (es) | Fenilpirazinonas como inhibidores de la btk, composicion farmaceutica que las contiene y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades autoinmunes e inflamatorias. | |
| AR076066A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| AR072272A1 (es) | Piridin-2-onas y piridazin-3-onas sustituidas utiles para el tratamiento de enfermedades autoinmunes e inflamatorias causadas por una activacion aberrante de las celulas b, y composiciones farmaceuticas que las contienen. | |
| AR086403A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| AR082590A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| AR074459A1 (es) | Pirrolopirazinil-ureas utiles para el tratamiento de enfermedades autoinmunes e inflamatorias. | |
| AR092536A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| AR069666A1 (es) | Derivados de imidazo[1, 2 - a]piridina e imidazo[1, 2 -b]piridazina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por las celulas b. | |
| AR084308A1 (es) | Compuestos insecticidas derivados de triazol | |
| AR087543A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| CO5700774A2 (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1 | |
| NO20085140L (no) | Nye indazolderivater som har spiro ringstruktur i sidekjede | |
| PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
| CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| CO6300861A2 (es) | Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos | |
| ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
| CO5590957A2 (es) | Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas | |
| ECSP003828A (es) | Antagonistas de neurokinina selectivos | |
| WO2003057688A3 (en) | Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators | |
| AR053710A1 (es) | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos | |
| AR011984A1 (es) | Esteres diarilicos, procesos para su produccion, composiciones herbicidas que los comprenden, metodos para controlar malezas, metodo para desecar una planta, y compuestos intermediarios para producir dichos esteres. | |
| AR083936A1 (es) | Derivados pirazolicos de bisamida aromaticas, composiciones insecticidas que los contienen y metodos de utilizacion de los mismos para combatir y controlar plagas | |
| WO2007071632A3 (en) | 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases | |
| AR061419A1 (es) | Compuestos de piridil amida sustituidos como moduladores del receptor de histamida h3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FA | Abandonment or withdrawal |